Multiply Labs Raises $75 Million as Physical AI Takes Aim at Biotech’s Manufacturing Bottleneck -( $AZN $KYTX $LEGN $NVS $TER )

Backed by AstraZeneca and Teradyne, the robotics company is betting that the next breakthrough in medicine will need a breakthrough on the factory floor.

Artificial intelligence can help design a promising medicine. It cannot deliver a dose by admiring its own calculations. That distinction sits at the heart of Multiply Labs’ newly announced $75 million Series B financing. The San Francisco company is building robotic systems to automate complex biological drug manufacturing, positioning itself at the intersection of two powerful investment themes: advanced medicines and physical AI. Announced October 6, the round brings its total funding to more than $100 million since its founding in 2016, Dr. Patrick Soon-Shiong and NantWorks led the financing, joined by new investors including AstraZeneca (AZN), Lingotto, Teradyne (TER), and Strange Ventures. Returning backers include Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund. The combination puts pharmaceutical expertise, robotics capital, and experienced venture investors around the same manufacturing problem. The bullish thesis is straightforward: as drug discovery becomes more productive and therapies become more complicated, the machinery that turns scientific promise into usable medicine could become increasingly valuable. Biotech has spent years looking for better molecules. Multiply Labs wants to make sure the factory can keep up.

The Investment Opportunity Between Discovery and Delivery

Multiply Labs is not developing another drug-discovery algorithm. It is building the infrastructure intended to move advanced therapies through the manufacturing steps that remain heavily dependent on skilled human operators. Those steps can include transferring materials between instruments, handling bags and syringes, collecting samples, and adding reagents. In cell therapy, such tasks are not merely administrative. They are part of a tightly controlled production sequence in which mistakes can jeopardize a patient’s dose. Strange Ventures’ investment essay describes this mismatch as sophisticated medical science operating on surprisingly manual infrastructure. Axios independently reported the $75 million financing and identified the broader significance: drugmakers are increasingly applying AI and automation to biologics manufacturing. For many, the attraction is an infrastructure business that could benefit from progress across multiple therapeutic programs rather than depend exclusively on one experimental medicine.That does not make manufacturing technology risk-free. It does give the investment thesis a different center of gravity: production capacity, repeatability, and adoption rather than the clinical outcome of a single molecule.

Robots That Work With Pharma’s Existing Equipment

Multiply Labs’ central design choice is to adapt robotics to the pharmaceutical industry’s existing instruments and workflows. According to the company, its robotic clusters connect manufacturing equipment inside an enclosed system and automate repetitive, carefully timed operations without requiring customers to build an entirely new facility or redesign their established processes. The pharmaceutical company owns and operates the cluster, retaining control over production and data rather than outsourcing manufacturing to Multiply Labs. That distinction matters commercially. An automation system that fits into a customer’s established manufacturing environment has a different adoption proposition from one that first requires the customer to replace it.The platform also uses imitation learning. Universal Robots, a technology partner, describes a process in which robots learn from recordings of scientists performing manufacturing tasks, then reproduce those actions with greater repeatability and parallel operation. The ambition is not to teach biology a new routine. It is to teach machines the routine biology already requires. There is considerable elegance in that approach. Pharmaceutical manufacturers generally prefer their innovation inside the medicine, not unexpectedly inside the production schedule.

The Numbers Behind the Bullish Case

Multiply Labs reports a 74% reduction in manufacturing cost per dose and throughput improvements of up to 100 times compared with manual manufacturing. Those figures are central to its pitch, but their scope deserves careful attention. A 2025 account from Universal Robots provides additional context. It describes a comparison of robotic and manual cell-therapy manufacturing that produced approximately 74% lower costs, citing work with University of California, San Francisco collaborators. The same account describes the 100-fold improvement specifically as patient doses per square foot of cleanroom. Strange Ventures also frames the throughput claim on a per-square-foot basis. That makes the investment argument more precise:

• Lower manufacturing costs could improve the economics of producing complex therapies.
• Higher output per square foot could increase the usefulness of expensive cleanroom capacity.
• Fewer manual handoffs could reduce opportunities for contamination and process variability.
• Automated data capture could make production records more consistent and easier to review.

These are reported performance claims, not proof that every installation will achieve the same results. A 74% reduction in manufacturing cost also does not mean a 74% reduction in the price charged to patients or insurers. Nevertheless, the direction is compelling. A platform that can improve cost, capacity, and consistency simultaneously addresses several manufacturing problems with one capital purchase.

Historical Perspective: From Personalized Breakthrough to Production Challenge

The manufacturing opportunity becomes clearer when viewed against the history of cell therapy. On August 30, 2017, the U.S. Food and Drug Administration approved Kymriah, developed by Novartis (NVS), as the first CAR T-cell therapy. Its initial approval covered certain children and young adults with acute lymphoblastic leukemia, That milestone demonstrated a new treatment model: a medicine manufactured from an individual patient’s own cells. Novartis’ original announcement described a production and supply-chain system built around collecting, freezing, transporting, and manufacturing those cells into a personalized treatment. The scientific advance came with an industrial challenge. Manufacturing CAR T-cell therapies involves cell collection, selection and activation, genetic modification, expansion, quality testing, and shipment back to the treatment site. These are complex biological production sequences, not conventional tablet-making operations. Multiply Labs was founded in 2016 as a Y Combinator startup, just before that first CAR T-cell approval. A decade later, its financing reflects an effort to develop the production infrastructure around this more demanding generation of medicines. The historical parallel is less about replacing scientists than about extending their work. Discovery creates the possibility of treatment. Manufacturing determines whether that possibility can be reproduced reliably. The company’s investors explicitly compare its ambition with the automation of automotive and semiconductor production. The analogy is useful as a statement of direction, not a guarantee of identical results: living cells are considerably less accommodating than standardized components.

A Strategic Investor Base With Industrial Logic

The financing is notable for the mix of investors, not just the amount raised.AstraZeneca (AZN) brings the perspective of a pharmaceutical company to the shareholder base. Teradyne (TER) adds an industrial-technology connection. Both participated as new investors in the Series B. The robotics relationship already has a practical dimension. Multiply Labs’ clusters use collaborative robot arms from Universal Robots, whose published account describes parallel operation, delicate handling, cleanroom compatibility, and integration with manufacturing software. Strange Ventures also identifies AstraZeneca (AZN), Legend Biotech (LEGN), and Kyverna Therapeutics (KYTX) as announced pharmaceutical collaborators. Those relationships suggest the company is engaging with prospective users of its technology, although collaborations should not automatically be treated as commercial orders or recurring revenue. For manyassessing an emerging industrial platform, that distinction is important. Strategic interest can open doors. Revenue still has to walk through them.

Beyond Cell Therapy: A Broader Biologics Platform

Cell and gene therapy are the company’s initial focus, but its stated expansion plans encompass antibodies, viral vectors, and messenger RNA therapies. The Series B proceeds will support increased manufacturing capacity, product development, and hiring across engineering, regulatory, and commercial functions, Multiply Labs` says the funding will help it progress from clinical-stage deployments toward commercial-scale production. That makes this round a scaling milestone, not evidence that the commercial transition is already complete. The upside lies in the platform’s potential breadth. If robotic clusters can adapt successfully across instruments, workflows, and therapeutic categories, Multiply Labs could become a supplier of manufacturing infrastructure to multiple drugmakers. The appeal is not that every new therapy must succeed. It is that successful therapies still have to be made.

What Many Should Watch Next

The next chapter should be measured in operating milestones rather than fundraising headlines. Key questions include:

• Commercial conversion: How many collaborations become paid installations and subsequent deployments?
• Customer economics: Can customers reproduce the reported savings and space-efficiency gains in their own production environments?
• Manufacturing reliability: Can the systems sustain consistent performance as workloads and deployment numbers grow?
• Platform breadth: How readily can capabilities demonstrated in cell therapy transfer to other biologics?
• Financial visibility: What are the economics of installation, service, support, and any recurring software arrangements?

The reviewed financing materials do not disclose valuation, revenue, profitability, customer concentration, or a detailed commercial revenue model. They also do not establish that strategic investments are financially material to the public-company backers. Those omissions do not erase the opportunity. They define the diligence still required.

Own the Capacity, Not Just the Concept

Multiply Labs offers a differentiated way to think about the AI-biotech opportunity. Its proposition is not simply that algorithms will discover better treatments. It is that more complex medicines will need better production infrastructure, and robotic systems could help deliver it with lower costs, greater consistency, and more useful manufacturing capacity. The financing, existing collaborations, and reported performance improvements provide a substantive foundation for that thesis, while commercial execution remains the decisive next test. Multiply Labs is privately held and has no public stock ticker. AstraZeneca (AZN), Teradyne (TER), Legend Biotech (LEGN), and Kyverna Therapeutics (KYTX) are relevant public-company connections, but their shares are not substitutes for direct ownership in Multiply Labs. For now, the most interesting investment signal is the shift in attention. The next generation of medicine may reward not only those who invent the treatment, but also those who solve the less glamorous problem of making enough of it. A brilliant therapy is an achievement. A reliably manufactured dose is what reaches the patient.

A Global Community. A Collective Voice. Direct Access. During JPMorgan Healthcare Conference 2027

Vista Partners’ sister company, Tribe Public (www.TribePublic.com), is expanding its CEO Presentation & Q&A Luncheon series during the annual J.P. Morgan Healthcare Conference (JPM2027) in San Francisco, the largest and most informative healthcare investment symposium in the industry. Tribe Public is now hosting four corporate-sponsored, RSVP-only Tribe Public CEO Presentation and Q&A Luncheon Events January 11-14. Tribe Public’s curated events will be taking place daily from noon to 2 p.m. at a location that is a short 5-minute Waymo to Uber ride from the conference. Each luncheon event is expected to welcome 50–80 attendees from the dedicated Tribe Public community that will, most likely, not be attending the chaos of other J.P. Morgan Healthcare Conference activities. However, the events or ‘company dedicated conferences’, will be meaningful and with thoughtful crowd that will help any company seeking to maximize their time and efforts to increase awareness, business development, and understanding amongst a broader globally connected community. One company will take center stage each day, giving its CEO a focused opportunity to share the company’s vision, highlight its latest developments and growth opportunities, and engage directly with a curated audience of Tribe Members through a live Q&A. For participating companies, this expanded series offers a compelling platform to elevate visibility, build relationships, and bring their stories to an engaged audience during a major week for healthcare. If companies are interested in presenting at one of these four events, then they should send an indication of interest to Events@TribePublic.com to schedule an introductory virtual meeting.

The Sources

1. Multiply Labs: $75 Million Series B Announcement
   Company announcement outlining the financing, investors, manufacturing platform, and expansion plans.
2. Business Wire: Multiply Labs Raises $75 Million Series B to Close the Gap Between Drug Discovery and Drug Manufacturing
   Company-issued press release distributed through Business Wire.
3. Multiply Labs: Robotic Biomanufacturing Infrastructure
   Company website describing its robotic manufacturing systems and technology.
4. Axios: Multiply Labs Raises $75 Million to Scale Pharma Manufacturing Robots
   Independent coverage of the financing. Full article requires a subscription.
5. The Strange Review: Why We Invested in Multiply Labs
   Strange Ventures’ investment thesis discussing manufacturing automation, pharmaceutical collaborations, and the company’s market opportunity.
6. Universal Robots: Robotics Transforms Cell Therapy, Multiply Labs Slashes Costs by 74%
   Technology partner’s account of the robotic platform, reported manufacturing savings, and cleanroom productivity.
7. National Cancer Institute: CAR T-Cell Therapy Approved for Some Children and Young Adults With Leukemia
   Historical context on the FDA’s August 2017 approval of the first CAR T-cell therapy.
8. Novartis: First-Ever FDA Approval for CAR T-Cell Therapy Kymriah
   Original announcement describing the approval and personalized manufacturing process.
9. PubMed Central: Kymriah, An Overview of the Clinical Development Journey
   Scientific background on the therapy’s development and manufacturing steps.